Summary of the 32. BVMA Symposium in Munich

Did you already know that the “Medizinforschungsgesetz” incorporates new regulations for radiation protection notifications? A streamlined procedure for these notifications aims at ensuring that radiation protection-relevant studies, e.g. with imaging end points based on PET or CT imaging, in Germany are approved at a similar speed as in other European countries.
This and many other aspects of the current situation in clinical research have been discussed at the 32. BVMA Symposium in Munich last week, most of them with an optimistic perspective for the next years. Germany is starting to catch up again, because more clinical trials in Germany will not only contribute to our BIP but also provide access to the newest therapies for many patients – many of us.

Many Thanks to BVMA – Bundesverband Medizinischer Auftragsinstitute e.V. for this energizing event!